Australian clinical research organization Nucleus Network announced Tuesday the commencement of dosing the first human participants for the Phase 1 trial of a COVID-19 vaccine on behalf of US -based biotechnology company Novavax. In April, authorities had anticipated that they planned to use their Matrix-M adjuvant to improve the immune response.
Novavax expects to have some results to share in July and that could pave the way for phase two trials to look at the impact on people with coronavirus and side effects.
The Phase I portion is a randomised, observer-blinded, placebo-controlled trial created to evaluate the immunogenicity and safety of NVX-CoV2373, both adjuvanted with Matrix-M and unadjuvanted, in around 130 healthy participants 18 to 59 years of age at two sites in Australia.
The Phase 2 trial will assess immunity, safety and COVID-19 disease reduction in a broader age range, Novavax said.
However, it seems that the coronavirus vaccine project is a promising one considering the fact that the company has got the investment to the tune of $388 million from the Coalition for Epidemic Preparedness Innovations for the same.
"We believe Novavax and Praha reflect the ideal complement of capabilities and expertise to advance innovative vaccines that are vitally needed at this critical time", said Cyrus Poonawalla, Chairman and Founder of his namesake group. Still other vaccine candidates are more old-fashioned, made with dead, whole virus. "The animal testing will take three months and results are expected by the end of August", said Dr. Kiat Rakrungtham, director of the Chulalongkorn University's Vaccine Research and Development Center, also part of the Thai COVID-19 vaccine research team, Xinhua reports. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).
NVX-CoV2373 has become the tenth vaccine against SARS-CoV-2 - the virus that causes COVID-19 - to reach the human testing stage, according to the World Health Organisation's latest update dated 22 May, which says another 114 candidates are in preclinical testing. Phase 1 will be a randomized, placebo-controlled trial to test the immunogenicity and safety of NVX-CoV2373. That the a number of vaccines transferring into human trials have been constructed utilizing quite a few completely different applied sciences is considered a constructive signal, elevating the likelihood that certainly one of them might succeed.
Still, nearly half of vaccine recipients reported fever, with 44% reporting fatigue and 39% reporting a headache. Different clinical tests are conducted around the world by different countries in the hope of finding an effective vaccine that will completely stop the spreading of the global coronavirus pandemic, which would save people's lives.
"We injected the vaccine into 13 long-tailed macaques on Saturday".
In addition, he said, the vaccine did not elicit a strong immune response. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
The Thai vaccine uses messenger RNA, which prompts body cells to produce antigens, molecules on the surface of viruses, that spur the immune system into action.